A Hungarian fund manager reports a stake above 5% in Protalix BioTherapeutics (PLX).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
HOLD Alapkezelo Zrt., a Hungarian investment fund management company, has reported a beneficial ownership stake of 5.2% in Protalix BioTherapeutics, Inc. (PLX). This stake, amounting to 4,157,791 shares, was measured against 80,571,642 common shares outstanding as of June 30, 2026. The filing indicates that HOLD Alapkezelo Zrt. holds sole voting and dispositive power over these shares.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.